SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Integra Investors of a Lead Plaintiff Deadline of November 13, 2023
Werte in diesem Artikel
NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders:
The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 11, 2019 and May 22, 2023.
If you suffered a loss on your investment in Integra, contact us about potential recovery by using the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/integra-class-action-submission-form/?prid=55406&wire=4
ABOUT THE ACTION: According to the complaint, defendants made false statements and/or concealed that Integra had failed to take sufficient measures to remediate the violations identified by the FDA in the November 2, 2018 Notice of Inspectional Observations on Form 483 (the "2018 Form 483"), the March 6, 2019 FDA issued warning letter (the "2019 Warning Letter"), and the November 12, 2021 FDA issued Form 483 (the "2021 Form 483"). As a result of those deficiencies, since March 2018, all products manufactured in the Boston Facility had the potential for higher-than-permitted levels of endotoxin and would need to be recalled. Moreover, the Company was not making progress towards obtaining its premarket approval ("PMA") indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies.
DEADLINE: November 13, 2023
Aggrieved Integra investors only have until November 13, 2023 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
E-Mail: vw@wongesq.com
View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-law-offices-of-vincent-wong-remind-integra-investors-of-a-lead-plaintiff-deadline-of-november-13-2023-301984887.html
SOURCE The Law Offices of Vincent Wong
Ausgewählte Hebelprodukte auf Integra LifeSciences
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Integra LifeSciences
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Integra LifeSciences Aktie News
Integra LifeSciences Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Integra LifeSciences nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.07.18 | Integra LifeSciences Buy | BTIG Research | |
| 05.01.18 | Integra LifeSciences Neutral | Cantor Fitzgerald | |
| 09.11.17 | Integra LifeSciences Sector Perform | RBC Capital Markets | |
| 30.06.17 | Integra LifeSciences Overweight | Cantor Fitzgerald | |
| 02.05.17 | Integra LifeSciences Sector Perform | RBC Capital Markets |